Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

CorMedix (CRMD) Shares Outstanding (2016 - 2025)

CorMedix (CRMD) has disclosed Shares Outstanding for 14 consecutive years, with $79.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 122954.55% to $79.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $79.3 million through Dec 2025, up 122954.55% year-over-year, with the annual reading at $79.3 million for FY2025, 122954.55% up from the prior year.
  • Shares Outstanding hit $79.3 million in Q4 2025 for CorMedix, up from $78.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $79.3 million in Q4 2025 to a low of $181622.0 in Q3 2021.
  • Historically, Shares Outstanding has averaged $31.5 million across 5 years, with a median of $38.1 million in 2021.
  • Biggest five-year swings in Shares Outstanding: plummeted 99.59% in 2024 and later skyrocketed 122954.55% in 2025.
  • Year by year, Shares Outstanding stood at $38.1 million in 2021, then plummeted by 99.52% to $181622.0 in 2022, then surged by 30079.19% to $54.8 million in 2023, then tumbled by 99.88% to $64411.0 in 2024, then surged by 122954.55% to $79.3 million in 2025.
  • Business Quant data shows Shares Outstanding for CRMD at $79.3 million in Q4 2025, $78.3 million in Q3 2025, and $6.6 million in Q2 2025.